Baseline characteristics of the molecular-profiling cohort
| . | ITT evaluable for molecular-profiling . | ITT population . | ||
|---|---|---|---|---|
| InO n = 43 . | SC n = 48 . | InO n = 164 . | SC n = 162 . | |
| Age, median (range), y | 49.0 (20.0-78.0) | 54.5 (20.0-76.0) | 46.5 (18.0-78.0) | 47.5 (18.0-78.0) |
| Male, n (%) | 26 (60.5) | 28 (58.3) | 91 (55.5) | 102 (63.0) |
| Race, n (%) | ||||
| White | 27 (62.8) | 39 (81.3) | 112 (68.3) | 120 (74.1) |
| Asian | 8 (18.6) | 3 (6.3) | 31 (18.9) | 24 (14.8) |
| Black | 1 (2.3) | 1 (2.1) | 4 (2.4) | 3 (1.9) |
| Other | 7 (16.3) | 5 (10.4) | 17 (10.4) | 15 (9.3) |
| ECOG PS, n (%) | ||||
| 0 | 14 (32.6) | 20 (41.7) | 62 (37.8) | 61 (37.7) |
| 1 | 25 (58.1) | 21 (43.8) | 81 (49.4) | 80 (49.4) |
| 2 | 4 (9.3) | 6 (12.5) | 21 (12.8) | 20 (12.3) |
| Missing | 0 | 1 (2.1) | 0 | 1 (0.6) |
| Salvage status, n (%) | ||||
| 1 | 30 (69.8) | 37 (77.1) | 111 (67.7) | 102 (63.0) |
| 2 | 13 (30.2) | 11 (22.9) | 51 (31.1) | 59 (36.4) |
| Missing | 0 | 0 | 2 (1.2) | 1 (0.6) |
| Duration of first remission, n (%) | ||||
| <12 mo | 24 (55.8) | 28 (58.3) | 96 (58.5) | 106 (65.4) |
| ≥12 mo | 19 (44.2) | 20 (41.7) | 68 (41.5) | 56 (34.6) |
| Response to prior induction regimen, n (%) | ||||
| Complete response | 35 (81.4) | 36 (75.0) | 121 (73.8) | 112 (69.1) |
| Partial response | 1 (2.3) | 1 (2.1) | 11(6.7) | 10 (6.2) |
| Stable disease | 0 | 0 | 1 (0.6) | 4 (2.5) |
| Resistant disease | 7 (16.3) | 11 (22.9) | 28 (17.1) | 30 (18.5) |
| Progressive disease | 0 | 0 | 3 (1.8) | 5 (3.1) |
| Unknown | 0 | 0 | 0 | 1 (0.6) |
| Received prior HSCT, n (%) | 10 (23.3) | 6 (12.5) | 29 (17.7) | 32 (19.8) |
| WBC count, median (range), ×103 cells/mm3 | 3.6 (0.4-27.4) | 4.4 (0.6-51.0) | 4.1 (0.0-47.4) | 4.0 (0.1-68.8) |
| Peripheral blood count, median (range), ×103/μL | 0 (0-7112.0) | 18.4 (0-23 664.0) | 0 (0-7112.0) | 18.4 (0-23 664.0) |
| No circulating blasts, n (%) | 23 (53.5) | 23 (47.9) | 71 (43.3) | 74 (45.7) |
| Bone marrow blasts, n (%) | ||||
| <50% | 17 (39.5) | 12 (25.0) | 53 (32.3) | 48 (29.6) |
| ≥50% | 25 (58.1) | 36 (75.0) | 10.9 (66.5) | 113 (69.8) |
| Missing | 1 (2.3) | 0 | 2 (1.2) | 1 (0.6) |
| CD22 expression on ALL blasts, n (%) | ||||
| ≥90 | 33 (76.7) | 33 (68.8) | 107 (65.2) | 93 (57.4) |
| 70% to <90% | 9 (20.9) | 8 (16.7) | 30 (18.3) | 18 (11.1) |
| <70% | 0 | 6 (12.5) | 5 (3.0) | 18 (11.1) |
| Missing | 1 (2.3) | 1 (2.1) | 22 (13.4) | 33 (20.4) |
| . | ITT evaluable for molecular-profiling . | ITT population . | ||
|---|---|---|---|---|
| InO n = 43 . | SC n = 48 . | InO n = 164 . | SC n = 162 . | |
| Age, median (range), y | 49.0 (20.0-78.0) | 54.5 (20.0-76.0) | 46.5 (18.0-78.0) | 47.5 (18.0-78.0) |
| Male, n (%) | 26 (60.5) | 28 (58.3) | 91 (55.5) | 102 (63.0) |
| Race, n (%) | ||||
| White | 27 (62.8) | 39 (81.3) | 112 (68.3) | 120 (74.1) |
| Asian | 8 (18.6) | 3 (6.3) | 31 (18.9) | 24 (14.8) |
| Black | 1 (2.3) | 1 (2.1) | 4 (2.4) | 3 (1.9) |
| Other | 7 (16.3) | 5 (10.4) | 17 (10.4) | 15 (9.3) |
| ECOG PS, n (%) | ||||
| 0 | 14 (32.6) | 20 (41.7) | 62 (37.8) | 61 (37.7) |
| 1 | 25 (58.1) | 21 (43.8) | 81 (49.4) | 80 (49.4) |
| 2 | 4 (9.3) | 6 (12.5) | 21 (12.8) | 20 (12.3) |
| Missing | 0 | 1 (2.1) | 0 | 1 (0.6) |
| Salvage status, n (%) | ||||
| 1 | 30 (69.8) | 37 (77.1) | 111 (67.7) | 102 (63.0) |
| 2 | 13 (30.2) | 11 (22.9) | 51 (31.1) | 59 (36.4) |
| Missing | 0 | 0 | 2 (1.2) | 1 (0.6) |
| Duration of first remission, n (%) | ||||
| <12 mo | 24 (55.8) | 28 (58.3) | 96 (58.5) | 106 (65.4) |
| ≥12 mo | 19 (44.2) | 20 (41.7) | 68 (41.5) | 56 (34.6) |
| Response to prior induction regimen, n (%) | ||||
| Complete response | 35 (81.4) | 36 (75.0) | 121 (73.8) | 112 (69.1) |
| Partial response | 1 (2.3) | 1 (2.1) | 11(6.7) | 10 (6.2) |
| Stable disease | 0 | 0 | 1 (0.6) | 4 (2.5) |
| Resistant disease | 7 (16.3) | 11 (22.9) | 28 (17.1) | 30 (18.5) |
| Progressive disease | 0 | 0 | 3 (1.8) | 5 (3.1) |
| Unknown | 0 | 0 | 0 | 1 (0.6) |
| Received prior HSCT, n (%) | 10 (23.3) | 6 (12.5) | 29 (17.7) | 32 (19.8) |
| WBC count, median (range), ×103 cells/mm3 | 3.6 (0.4-27.4) | 4.4 (0.6-51.0) | 4.1 (0.0-47.4) | 4.0 (0.1-68.8) |
| Peripheral blood count, median (range), ×103/μL | 0 (0-7112.0) | 18.4 (0-23 664.0) | 0 (0-7112.0) | 18.4 (0-23 664.0) |
| No circulating blasts, n (%) | 23 (53.5) | 23 (47.9) | 71 (43.3) | 74 (45.7) |
| Bone marrow blasts, n (%) | ||||
| <50% | 17 (39.5) | 12 (25.0) | 53 (32.3) | 48 (29.6) |
| ≥50% | 25 (58.1) | 36 (75.0) | 10.9 (66.5) | 113 (69.8) |
| Missing | 1 (2.3) | 0 | 2 (1.2) | 1 (0.6) |
| CD22 expression on ALL blasts, n (%) | ||||
| ≥90 | 33 (76.7) | 33 (68.8) | 107 (65.2) | 93 (57.4) |
| 70% to <90% | 9 (20.9) | 8 (16.7) | 30 (18.3) | 18 (11.1) |
| <70% | 0 | 6 (12.5) | 5 (3.0) | 18 (11.1) |
| Missing | 1 (2.3) | 1 (2.1) | 22 (13.4) | 33 (20.4) |
ECOG PS, Eastern Cooperative Oncology Group performance status; WBC, white blood cell.